Cassava sciences launches clinical website to support phase 3 studies of oral simufilam in alzheimer's disease

Austin, texas, dec. 23, 2021 (globe newswire) -- cassava sciences, inc., (nasdaq: sava) a biotechnology company, today announced the launch of a new clinical website, called www.rethink-alz.com. rethink-alz.com is intended to provide access, visibility and information on cassava sciences' phase 3 safety and efficacy studies of oral simufilam in people with alzheimer's disease. simufilam is a new oral drug candidate for the proposed treatment of mild-to-moderate alzheimer's disease.
SAVA Ratings Summary
SAVA Quant Ranking